1. Ditah I, Ditah F, Devaki P, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination survey 2001 through 2010. J Hepatol 2014;60:691–698.

2. Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 2022;7:396–415.

3. Kim DY, Kim IH, Jeong SH, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013;33:586–594.

4. Kim KA, Lee JS. Prevalence, awareness, and treatment of hepatitis C virus infection in South Korea: evidence from the Korea national health and nutrition examination survey. Gut Liver 2020;14:644–651.

6. Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol 2019;4:135–184.

7. Pawlotsky JM, Ramers CB, Dillon JF, Feld JJ, Lazarus JV. Simplification of care for chronic hepatitis C virus infection. Semin Liver Dis 2020;40:392–402.

8. Ghany MG, Morgan TR, AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 2020;71:686–721.

9. Colin C, Lanoir D, Touzet S, et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001;8:87–95.

10. Alter MJ, Kuhnert WL, Finelli L, Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003;52:1–1315quiz CE1–CE4. 11. Hsu HH, Gonzalez M, Foung SK, Feinstone SM, Greenberg HB. Antibodies to hepatitis C virus in low-risk blood donors: implications for counseling positive donors. Gastroenterology 1991;101:1724–1727.

12. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691–1696.

13. Kim YK, Kim BH, Jin ES, et al. Positive predictability and predictive factors of the third generation anti-hepatitis C virus (HCV) ELISA test for HCV infection. Korean J Gastroenterol 2005;45:181–188.

14. Moretti M, Pieretti B, Masucci A, Sisti D, Rocchi M, Delprete E. Role of signal-to-cutoff ratios in hepatitis C virus antibody detection. Clin Vaccine Immunol 2012;19:1329–1331.

15. Bischoff F, Koch M, Araújo F. Decision on conducting HCV immunoblot and HCV viral load tests dependent upon the result of the screening tests. J Virol Microbiol 2013;2013:332501.

16. Dufour DR, Talastas M, Fernandez MD, Harris B, Strader DB, Seeff LB. Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection. Clin Chem 2003;49:479–486.

17. Lai KK, Jin M, Yuan S, Larson MF, Dominitz JA, Bankson DD. Improved reflexive testing algorithm for hepatitis C infection using signal-to-cutoff ratios of a hepatitis C virus antibody assay. Clin Chem 2011;57:1050–1056.

18. Contreras AM, Ochoa-Jiménez RJ, Celis A, et al. High antibody level: an accurate serologic marker of viremia in asymptomatic people with hepatitis C infection. Transfusion 2010;50:1335–1343.

19. Contreras AM, Tornero-Romo CM, Toribio JG, et al. Very low hepatitis C antibody levels predict false-positive results and avoid supplemental testing. Transfusion 2008;48:2540–2548.

20. Logvinoff C, Major ME, Oldach D, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 2004;101:10149–10154.

21. Nikolaeva LI, Blokhina NP, Tsurikova NN, et al. Virus-specific antibody titres in different phases of hepatitis C virus infection. J Viral Hepat 2002;9:429–437.

22. Lu SN, Tung HD, Chen TM, et al. Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion? J Viral Hepat 2004;11:563–570.

23. Choi MS, Lee K, Hong YJ, Song EY, Kim DS, Song J. The role of the signal-to-cutoff ratio in automated anti-HCV chemiluminescent immunoassays by referring to the nucleic acid amplification test and the recombinant immunoblot assay. Ann Lab Med 2018;38:466–472.

24. Centers for Disease Control and Prevention (CDC). Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013;62:362–365.

25. Seo YS, Jung ES, Kim JH, et al. Significance of anti-HCV signal-to-cutoff ratio in predicting hepatitis C viremia. Korean J Intern Med 2009;24:302–308.

26. Lee CH, Shin HP, Lee JI, et al. Predicting factors of present hepatitis C virus infection among patients positive for the hepatitis C virus antibody. Clin Mol Hepatol 2013;19:376–381.

27. Kim S, Kim JH, Yoon S, Park YH, Kim HS. Clinical performance evaluation of four automated chemiluminescence immunoassays for hepatitis C virus antibody detection. J Clin Microbiol 2008;46:3919–3923.

28. Cho YK, Kim S, Kim HO, Choi DS, Kim HS, Park Y. Comparative evaluation of Elecsys, Atellica, and Alinity assays for measuring the anti-hepatitis C virus (HCV) antibody. J Clin Virol 2021;141:104910.

29. Kim B, Ahn HJ, Choi MH, Park Y. Retrospective analysis on the diagnostic performances and signal-to-cut-off ratios of the Elecsys Anti-HCV II assay. J Clin Lab Anal 2018;32:e22165.

30. Huang Y, Pan H, Gao Q, Lv P, Xu X, Zhao Z. The role of a two-assay serological testing strategy for anti-HCV screening in low-prevalence populations. Sci Rep 2021;11:8689.